ASP Isotopes Inc. Common Stock ASPI · Stock Open ASP Isotopes Inc. Common Stock in new tab
ASP Isotopes Inc. Common Stock Analysis (ASPI)
Is ASP Isotopes Inc. Common Stock a good investment? ASP Isotopes Inc. Common Stock (ASPI) is currently trading at 3.26 USD. Market analysts have a consensus price target of 13.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: ASP Isotopes Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.71.
Investor FAQ
Does ASP Isotopes Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is ASP Isotopes Inc. Common Stock?
ASP Isotopes Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.44.
Company Profile
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes in South Africa,Hong Kong, and United States. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-68, Nickel-64, and Xenon-129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. The company was incorporated in 2021 and is based in Dallas, Texas.
Community Discussion